What is consolidation therapy for the treatment of B-cell mantle cell lymphoma (MCL)?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

In patients who are candidates for it, high-dose therapy followed with autologous stem cell rescue shouild be considered.

Second-line therapy

Second-line therapy regimens include the following:

  • Bendamustine ± rituximab
  • Bendamustine, bortezomib, and rituximab (category 2B)
  • Bortezomib ± rituximab
  • Cladribine + rituximab
  • FC (fludarabine, cyclophosphamide) ± rituximab (category 3)
  • Ibrutinib
  • Ibrutinib, lenalidomide, rituximab (category 2B)
  • Lenalidomide ± rituximab
  • PCR (pentostatin, cyclophosphamide, rituximab) (category 3)
  • PEPC (prednisone, etoposide, procarbazine, cyclophosphamide) ± rituximab (category 3)
  • Venetoclax
  • See second-line therapy for DLBCL (BCEL-C 2 of 4) without regard to transplantability

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!